130 related articles for article (PubMed ID: 38278470)
1. Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-α signaling axis in triple-negative breast cancer.
Liu C; Qian X; Yu C; Xia X; Li J; Li Y; Xie Y; Gao G; Song Y; Zhang M; Xue H; Wang X; Sun H; Liu J; Deng W; Guo X
Cancer Lett; 2024 Apr; 586():216642. PubMed ID: 38278470
[TBL] [Abstract][Full Text] [Related]
2. STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression.
Song YM; Qian XL; Xia XQ; Li YQ; Sun YY; Jia YM; Wang J; Xue HQ; Gao GS; Wang XZ; Zhang XM; Guo XJ
Breast Cancer Res Treat; 2022 Nov; 196(1):45-56. PubMed ID: 36056297
[TBL] [Abstract][Full Text] [Related]
3. Proteomic, single-cell and bulk transcriptomic analysis of plasma and tumor tissues unveil core proteins in response to anti-PD-L1 immunotherapy in triple negative breast cancer.
Li Y; Yue L; Zhang S; Wang X; Zhu YN; Liu J; Ren H; Jiang W; Wang J; Zhang Z; Liu T
Comput Biol Med; 2024 Jun; 176():108537. PubMed ID: 38744008
[TBL] [Abstract][Full Text] [Related]
4. p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target.
Deng S; Wang M; Wang C; Zeng Y; Qin X; Tan Y; Liang B; Cao Y
Mol Biol Rep; 2023 Jan; 50(1):577-587. PubMed ID: 36352176
[TBL] [Abstract][Full Text] [Related]
5. TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity.
Liu Q; Chung S; Murata MM; Han B; Gao B; Zhang M; Lee TY; Chirshev E; Unternaehrer J; Tanaka H; Giuliano AE; Cui Y; Cui X
Int J Biol Sci; 2022; 18(10):4203-4218. PubMed ID: 35844787
[No Abstract] [Full Text] [Related]
6. Liposomal ATM siRNA delivery for enhancing triple-negaitive breast cancer immune checkpoint blockade therapy.
Yu D; Wang H; Liu H; Xu R
J Biomater Appl; 2023 May; 37(10):1835-1846. PubMed ID: 37016537
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
[TBL] [Abstract][Full Text] [Related]
10. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
11. Let-7a/cMyc/CCAT1/miR-17-5p Circuit Re-sensitizes Atezolizumab Resistance in Triple Negative Breast Cancer through Modulating PD-L1.
Selem NA; Nafae H; Manie T; Youness RA; Gad MZ
Pathol Res Pract; 2023 Aug; 248():154579. PubMed ID: 37301086
[TBL] [Abstract][Full Text] [Related]
12. ATM kinase regulates tumor immunoreactions in lymphocyte-predominant breast cancer through modulation of NKG2D ligand and TNF cytokines on tumor cells.
Xu P; Sun Y; Song Y; Jiao J; Shen B; Li W; Jiang C; Li Y; Zhang X; Yu J; Fu L; Guo X
Med Mol Morphol; 2020 Dec; 53(4):210-220. PubMed ID: 32067111
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer.
Wang C; Xu YH; Xu HZ; Li K; Zhang Q; Shi L; Zhao L; Chen X
J Nanobiotechnology; 2023 Dec; 21(1):476. PubMed ID: 38082443
[TBL] [Abstract][Full Text] [Related]
14. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
Juliá EP; Amante A; Pampena MB; Mordoh J; Levy EM
Front Immunol; 2018; 9():2140. PubMed ID: 30294328
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway.
Shen M; Xu Z; Xu W; Jiang K; Zhang F; Ding Q; Xu Z; Chen Y
J Exp Clin Cancer Res; 2019 Apr; 38(1):149. PubMed ID: 30961670
[TBL] [Abstract][Full Text] [Related]
16. Regulation of programmed death ligand 1 (PD-L1) expression by TNF-related apoptosis-inducing ligand (TRAIL) in triple-negative breast cancer cells.
Pimentel JM; Zhou JY; Wu GS
Mol Carcinog; 2023 Feb; 62(2):135-144. PubMed ID: 36239572
[TBL] [Abstract][Full Text] [Related]
17. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
Chen XY; Li B; Wang Y; Jin J; Yang Y; Huang LH; Yang MD; Zhang J; Wang BY; Shao ZM; Ni T; Huang SL; Hu XC; Tao ZH
Cancer Commun (Lond); 2023 Sep; 43(9):1003-1026. PubMed ID: 37434394
[TBL] [Abstract][Full Text] [Related]
18. [Plasma exosomal miR-335-5p serves as a diagnostic indicator and inhibits immune escape in triple-negative breast cancer].
Chen T; Dong Y; Wu X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):347-356. PubMed ID: 35583065
[TBL] [Abstract][Full Text] [Related]
19. c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun.
Xie X; Kaoud TS; Edupuganti R; Zhang T; Kogawa T; Zhao Y; Chauhan GB; Giannoukos DN; Qi Y; Tripathy D; Wang J; Gray NS; Dalby KN; Bartholomeusz C; Ueno NT
Oncogene; 2017 May; 36(18):2599-2608. PubMed ID: 27941886
[TBL] [Abstract][Full Text] [Related]
20. The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer.
Li J; Zhang D; Liu Z; Wang Y; Li X; Wang Z; Liang G; Yuan X; Li Y; Komorowski AL; Rozen WM; Orlandi A; Takabe K; Franceschini G; Jerusalem G; Wang X
Ann Transl Med; 2023 Jan; 11(2):83. PubMed ID: 36819490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
